NCT06378190View on ClinicalTrials.gov

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2030

Conditions
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Interventions
BIOLOGICAL

CAR-T cells therapy

CAR-T cells therapy

Trial Locations (8)

31008

RECRUITING

Clínica Universidad de Navarra, Pamplona

37007

RECRUITING

Salamanca University Health Care Complex, Salamanca

Unknown

NOT_YET_RECRUITING

Institut Català d'Oncologia Hospital, L'Hospitalet de Llobregat

NOT_YET_RECRUITING

Virgen de la Arrixaca University Hospital, El Palmar

NOT_YET_RECRUITING

University Hospital of Navarra, Pamplona

NOT_YET_RECRUITING

Hospital Clínic, Barcelona

NOT_YET_RECRUITING

Fundación Jiménez Díaz Hospital, Madrid

NOT_YET_RECRUITING

Virgen del Rocio Hospital, Seville

All Listed Sponsors
collaborator

Spanish Clinical Research Network - SCReN

NETWORK

collaborator

Fundación Canaria de Investigación Sanitaria

OTHER

collaborator

Fundación para la Investigación Biomédica del Hospital 12 de Octubre

UNKNOWN

lead

Instituto de Investigación Biomédica de Salamanca

OTHER